MedTech Breakthrough: SS Innovations achieves India’s first human telesurgery trial

New Delhi: SS Innovations has made history by completing India’s first human telesurgery trial, demonstrating a groundbreaking leap in medical technology.

The historic telesurgery trial, a robotic cholecystectomy, was conducted flawlessly between the World Laparoscopy Hospital and the SSI Headquarters, covering a distance of 5 kilometers. This surgery utilized Airtel’s fiberoptic network, highlighting the potential for quality healthcare delivery in remote areas, further promoting the Make in India initiative by showcasing indigenous innovation on an international stage.

Alongside this significant achievement, the company has unveiled its latest advancement, the SSI Mantra 3. This cutting-edge system is set to revolutionize the field of robotic surgery with its advanced features, enhancing precision and patient outcomes.

The SSI Mantra 3 boasts five slimmer robotic arms and an immersive 3D HD headset, providing surgeons with superior optics and control. The vision cart, which offers 3D 4K vision to the entire surgical team, further ensures unmatched precision. The SSI Mantra 3 enables smaller incisions, resulting in less pain, minimal blood loss, reduced scarring, faster recovery, and shorter hospital stays. These innovations aim to make advanced surgical technologies more accessible and affordable for healthcare institutions globally.

In a notable development, Dr. Fredric Moll, widely regarded as the father of surgical robotics and founder of Intuitive Surgical, has joined SS Innovations International Inc. as a Board Member and Vice Chairman. Dr. Moll’s contributions to the field of robotic surgery have been instrumental in advancing the technology.

Dr. Sudhir Srivastava, founder, chairman, and CEO of SS Innovations, commented, “With the launch of SSI Mantra 3 and the successful completion of India’s first human trial in soft tissue telesurgery, we reaffirm our commitment to driving advanced innovation and accessibility in robotic surgeries. These achievements underline our belief in the power of our indigenous technology to transform healthcare across the globe. We are proud to contribute to the Make in India initiative and remain dedicated to advancing the boundaries of surgical excellence.”

Dr. Fredric Moll added, “I would like to extend my heartfelt congratulations to Dr. Srivastava and the entire SSI team on the successful launch of SSI Mantra 3. Achieving this milestone in less than five months is truly commendable. I feel incredibly fortunate to be part of SSI, contributing to this cutting-edge robotic system.”

Dr Mylswamy Annaduari, former director of the ISRO Satellite Centre, emphasized “The launch of SSI Mantra 3 signifies the future of India, and SSI has truly made it a reality. The Mantra 3 system represents the convergence of medical science in India and extends Indian innovation to surgeons worldwide. It is an affordable innovation, precisely what India needed.”

Dr Sudhir K Rawal, Medical Director of RGCIRC, stated, “From Mantra One to Mantra Three, the evolution has been remarkable. SSI came in and broke the monopoly, revolutionizing the field, and this is the best advancement I could have hoped for in my surgical career. The ease of using the Mantra system is phenomenal, which is why it is gaining traction beyond borders.”

Dr Naresh Trehan, Chairman of Medanta, and Dr. Devi Shetty, Founder of Narayana Healthcare, also lauded Dr. Srivastava’s vision and dedication.

Prof Dr. Somashekhar SP of Aster DM Healthcare remarked, “SSI has achieved the essence of the ‘Made In India, For The World’ with the launch of SSI Mantra 3. SSI has created the best technology robot at an affordable rate for the global market, all made in India. The release of Mantra 3 represents the pinnacle of this ongoing evolution, offering the best in technology.”